Ameriprise’s Rigel Pharmaceuticals RIGL Stock Holding History

Ameriprise’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$226K	Buy	+5,638	New	+$174K	﹤0.01%	3925
2022 Q2	–	Sell	-37,250	Closed	-$1.11M	–	3976
2022 Q1	$1.11M	Buy	37,250 +10,970	+42%	+$297K	﹤0.01%	3166
2021 Q4	$696K	Buy	+26,280	New	+$793K	﹤0.01%	3408
2020 Q1	–	Sell	-7,383	Closed	-$158K	–	3721
2019 Q4	$158K	Buy	+7,383	New	+$152K	﹤0.01%	3610
2014 Q4	–	Sell	-11	Closed	–	–	4258
2014 Q3	$0	Sell	11 -3	-21%	-$85	﹤0.01%	5878
2014 Q2	$1K	Buy	+14	New	+$476	﹤0.01%	5370
2013 Q4	–	Sell	-543	Closed	-$19K	–	5384
2013 Q3	$19K	Hold	543	–	–	﹤0.01%	4454
2013 Q2	$18K	Buy	+543	New	+$24.6K	﹤0.01%	4361

Other funds holding RIGL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ameriprise's RIGL Position: Q2 2026 in Review

Ameriprise opened a new position in Rigel Pharmaceuticals (RIGL) in Q2 2026: 5,638 shares worth $226K. The stake represents ﹤0.01% of the portfolio and ranks #3925 among its holdings. This is a return to the name: Ameriprise previously reported a position in RIGL as recently as Q1 2022.

Ameriprise first reported a position in RIGL in Q2 2013 and has held it in 8 quarters since. The position peaked at $1.11M in Q1 2022. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

Ameriprise held 5,638 shares of Rigel Pharmaceuticals worth $226K as of Q2 2026.
Rigel Pharmaceuticals was a new Ameriprise position in Q2 2026.
Rigel Pharmaceuticals made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3925 holding.
Ameriprise first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 8 quarters since.
Ameriprise's Rigel Pharmaceuticals position peaked at $1.11M in Q1 2022.
156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.